
|Videos|December 23, 2020
ASH 2020 Updates: Improving Outcomes in TIE-NDMM
Author(s)Targeted Oncology
Implications for assessing MRD status in patients with transplant-ineligible myeloma and treating appropriate patients with the combination of daratumumab, lenalidomide, and dexamethasone.





































